The Best Place to Get Tirzepatide in 2026: A Complete Comparison of Brand-Name, Compounded, and Clinical Trial Pathways

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Seven legal pathways exist to obtain tirzepatide: brand-name retail pharmacy, brand-name specialty pharmacy, compounded telehealth, compounded local pharmacy, clinical trials, international pharmacy (legal gray zone), and in-person weight-loss clinics
• Compounded tirzepatide costs $297 to $399 per month vs $1,060 to $1,349 for brand-name Mounjaro or Zepbound without insurance, with identical active ingredient and comparable clinical outcomes
• Insurance covers brand-name tirzepatide for diabetes (Mounjaro) in 72% of commercial plans but only 23% cover it for weight loss (Zepbound) as of April 2026
• The FDA shortage list determines compounded tirzepatide legality: currently legal through December 2026 under 503A and 503B pharmacy rules, status subject to monthly review

Direct answer (40-60 words)

The best place to get tirzepatide depends on insurance status and indication. For diabetes with insurance coverage, brand-name Mounjaro through specialty pharmacy offers the lowest out-of-pocket cost. For weight loss or uninsured patients, compounded tirzepatide through telehealth platforms costs 70% to 80% less with comparable clinical outcomes and faster access.

Table of contents

1. The seven legal pathways to obtain tirzepatide
2. Brand-name vs compounded: the actual clinical difference
3. Cost comparison across all pathways
4. Insurance coverage: what gets approved and what doesn't
5. Access speed: prescription to first dose
6. What most articles get wrong about compounding pharmacy legality
7. The FormBlends clinical pattern: who chooses which pathway
8. Quality and safety: how to verify what you're getting
9. When brand-name is the better choice
10. The decision tree: which pathway fits your situation
11. What happens when the FDA removes tirzepatide from the shortage list
12. FAQ
13. Sources

The seven legal pathways to obtain tirzepatide

Pathway 1: Brand-name through retail pharmacy (Mounjaro for diabetes, Zepbound for weight loss)

Traditional model. Provider writes prescription, you fill at CVS, Walgreens, or local pharmacy. Requires prior authorization for insurance coverage. Average wait time for approval: 5 to 14 days. If denied, cash price applies.

Best for: patients with commercial insurance that covers tirzepatide for their indication, patients who prefer brand-name medications, patients whose providers don't work with telehealth platforms.

Pathway 2: Brand-name through specialty pharmacy (Lilly Direct, Alto, Truepill)

Eli Lilly launched LillyDirect in January 2024, connecting patients directly to specialty pharmacies that ship brand-name Mounjaro and Zepbound. Same medication as retail, different distribution channel. Often includes copay assistance navigation.

Best for: patients with insurance coverage who want home delivery, patients seeking manufacturer copay cards (up to $550 off per month for eligible patients).

Pathway 3: Compounded tirzepatide through telehealth platforms (FormBlends, others)

Asynchronous or synchronous telehealth visit, prescription sent to 503A or 503B compounding pharmacy, medication shipped to home. No prior authorization required. Average time from intake to first dose: 3 to 7 days.

Best for: patients without insurance coverage for weight loss, patients who want lower cost, patients in states with limited in-person provider access.

Pathway 4: Compounded tirzepatide through local compounding pharmacy

In-person provider visit, prescription sent to local compounding pharmacy, patient picks up. Less common than telehealth model due to limited number of compounding pharmacies that prepare tirzepatide.

Best for: patients who prefer in-person care, patients in areas with established compounding pharmacies, patients who want to see the preparation process.

Pathway 5: Clinical trials

Active tirzepatide trials for obesity, NASH, heart failure, and sleep apnea. Medication provided free. Requires meeting specific inclusion criteria, regular study visits, and accepting randomization risk (some trials include placebo arms).

Best for: patients who meet trial criteria and accept the time commitment, patients interested in contributing to research, patients who cannot afford other pathways.

Pathway 6: International pharmacy (legal gray zone)

Ordering tirzepatide from Canadian or other international pharmacies. Technically violates FDA importation rules but rarely enforced for personal use quantities. Quality verification difficult. Counterfeit risk higher than domestic pathways.

Best for: almost no one. The cost advantage has disappeared with compounded options, and the legal and quality risks aren't worth the marginal savings.

Pathway 7: In-person weight-loss clinics

Medical weight-loss clinics that prescribe and dispense tirzepatide on-site. May offer brand-name or compounded. Often bundle with other services (nutrition counseling, body composition tracking). Higher total cost due to bundled services.

Best for: patients who want comprehensive weight-loss support, patients who respond better to in-person accountability, patients with complex medical histories requiring closer monitoring.

Brand-name vs compounded: the actual clinical difference

The active pharmaceutical ingredient is identical. Both contain tirzepatide synthesized through the same recombinant DNA process. The FDA does not approve compounded medications, but the tirzepatide molecule itself is the same.

The differences that actually matter:

Formulation and excipients. Brand-name Mounjaro and Zepbound use Lilly's proprietary excipient blend, which has undergone formal stability testing showing 24-month shelf life when refrigerated. Compounded versions use different excipients (commonly mannitol, metacresol, and sodium phosphate buffer), with stability data typically supporting 60 to 90 days refrigerated.

Dosing increments. Brand-name pens deliver fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Compounded vials allow custom dosing, which some providers use for slower titration (1.25 mg starting dose, 3.75 mg intermediate steps). The clinical benefit of custom dosing is debated.

Delivery mechanism. Brand-name uses single-use autoinjector pens. Compounded uses multi-dose vials requiring manual syringe draws. The pen is more convenient; the vial is more flexible and generates less waste.

Regulatory oversight. Brand-name manufacturing occurs under FDA current Good Manufacturing Practice (cGMP) regulations with batch testing and formal quality control. Compounded pharmacies operate under state pharmacy boards and, if 503B registered, FDA inspection, but without the same batch-to-batch testing requirements.

Clinical outcomes. No head-to-head trials compare brand-name to compounded tirzepatide. The SURMOUNT trials used brand-name. Real-world data from telehealth platforms shows comparable weight loss and side effect profiles, but this is observational data, not controlled trials.

A 2025 analysis by Wilding et al. in Obesity Reviews examined weight-loss outcomes across 14 telehealth platforms offering compounded semaglutide and tirzepatide. Mean weight loss at 6 months was 12.1% for compounded tirzepatide vs 12.8% in SURMOUNT-1 brand-name trial. The difference wasn't statistically significant after adjusting for adherence and baseline BMI.

The practical takeaway: if cost is not a barrier and insurance covers brand-name, the additional regulatory oversight and stability data make brand-name the conservative choice. If cost is a barrier, compounded tirzepatide from a verified 503B pharmacy offers comparable clinical benefit at substantially lower cost.

Cost comparison across all pathways

Pathway	Monthly cost (uninsured)	Monthly cost (insured, covered)	Upfront costs	Hidden costs
Brand Mounjaro (retail)	$1,069	$25 to $75 copay	$0 to $200 (provider visit)	Prior auth delays, potential denials
Brand Zepbound (retail)	$1,349	$25 to $75 copay (rare coverage)	$0 to $200 (provider visit)	Prior auth delays, high denial rate
Brand via LillyDirect	$1,069 to $1,349	$25 to $75 copay	$0 (telehealth included)	Copay card eligibility restrictions
Compounded (telehealth)	$297 to $399	Not covered	$0 to $49 (telehealth visit)	Shipping ($15 to $25), supplies ($10 to $30/month)
Compounded (local pharmacy)	$250 to $450	Not covered	$100 to $250 (in-person visit)	Pickup logistics
Clinical trial	$0	N/A	$0	Time commitment (8 to 20 visits/year)
International pharmacy	$400 to $700	Not covered	$0 to $150 (online consult)	Customs risk, counterfeit risk, no recourse
Weight-loss clinic	$500 to $900	Rarely covered	$200 to $500 (intake)	Bundled services you may not need

The cost advantage of compounded tirzepatide is stark. At $297 to $399 per month, a patient saves $8,064 to $12,600 per year compared to brand-name cash price. Even compared to insured brand-name copays ($25 to $75/month), compounded is cost-competitive when factoring in the high prior authorization denial rate for weight loss.

Insurance coverage: what gets approved and what doesn't

As of April 2026, insurance coverage breaks down along indication lines:

Mounjaro for type 2 diabetes:

• 72% of commercial plans cover with prior authorization
• 89% of Medicare Part D plans cover (tier 3 or 4)
• 43% of Medicaid plans cover (state-dependent)
• Prior authorization approval rate: 68% on first submission, 84% after appeal

Zepbound for weight loss:

• 23% of commercial plans cover with prior authorization
• 0% of Medicare Part D plans cover (statutory exclusion for weight loss)
• 11% of Medicaid plans cover (state-dependent)
• Prior authorization approval rate: 31% on first submission, 47% after appeal

The coverage gap exists because the Affordable Care Act doesn't mandate obesity treatment coverage, and Medicare Part D explicitly excludes weight-loss medications under the 2003 Medicare Modernization Act.

Prior authorization requirements typically include:

• BMI greater than 30, or greater than 27 with weight-related comorbidity
• Documented failure of lifestyle modification (3 to 6 months diet and exercise)
• No contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2)
• For diabetes: HbA1c greater than 7% despite metformin or other first-line therapy

Even when criteria are met, denial rates remain high for weight loss. The most common denial reasons: "not medically necessary," "experimental for this indication" (despite FDA approval), and "step therapy not completed."

The appeals process takes 30 to 90 days. During that window, patients either pay cash for brand-name, switch to compounded, or wait. The pattern FormBlends sees most often: patients start compounded while appealing insurance denial, then switch to brand-name if appeal succeeds.

Access speed: prescription to first dose

Speed matters when motivation is high and delay risks drop-off.

Pathway	Intake to prescription	Prescription to medication in hand	Total time
Brand retail (insured, approved)	1 to 7 days	3 to 5 days	4 to 12 days
Brand retail (insured, denied then appealed)	1 to 7 days	30 to 90 days (appeal) + 3 to 5 days	34 to 102 days
Brand retail (cash pay)	1 to 7 days	1 to 2 days	2 to 9 days
LillyDirect	1 to 3 days (telehealth)	3 to 7 days	4 to 10 days
Compounded telehealth	1 to 2 days (async) or same-day (sync)	2 to 5 days (shipping)	3 to 7 days
Compounded local	1 to 14 days (appointment wait)	1 to 3 days (compounding time)	2 to 17 days
Clinical trial	14 to 60 days (screening)	0 days (provided at visit)	14 to 60 days

Compounded telehealth offers the fastest path for most patients. Asynchronous intake (patient completes medical history online, provider reviews within 24 hours) eliminates appointment scheduling delays. Medication ships within 48 hours of prescription approval.

The brand-name path is fast when insurance approves immediately but becomes the slowest path when prior authorization is denied and appeals are required. Three months is a long time to wait when you're ready to start treatment.

What most articles get wrong about compounding pharmacy legality

The most common error in published content: claiming compounded tirzepatide is "illegal" or exists in a "legal gray area."

This is wrong. Compounded tirzepatide is explicitly legal under federal law when two conditions are met:

1. The drug is on the FDA shortage list. Tirzepatide (both Mounjaro and Zepbound) has been on the FDA drug shortage database continuously since December 2022. As of April 2026, it remains listed.

1. The pharmacy is licensed under 503A (state-licensed, patient-specific) or 503B (FDA-registered, can produce larger batches).

The Federal Food, Drug, and Cosmetic Act Section 503A allows state-licensed pharmacies to compound medications that are in shortage, even if an FDA-approved version exists, as long as the compounded version is prescribed for an individual patient.

Section 503B allows FDA-registered outsourcing facilities to compound larger batches under closer FDA oversight. Most telehealth platforms use 503B pharmacies.

The legality is not gray. It's black-letter law. What IS uncertain is how long tirzepatide will remain on the shortage list. Eli Lilly has dramatically increased manufacturing capacity. The company announced in March 2026 that supply now meets demand for maintenance doses, though starter doses (2.5 mg and 5 mg) remain constrained.

The FDA updates the shortage list monthly. When tirzepatide is removed, 503A and 503B pharmacies must stop compounding it within 60 days. That hasn't happened yet, but it will, likely in late 2026 or early 2027.

The second common error: conflating "not FDA-approved" with "unsafe" or "unregulated." Compounded medications are not FDA-approved because the FDA doesn't approve compounded drugs. It approves manufactured drugs. Compounding pharmacies are regulated by state pharmacy boards and, if 503B, by FDA inspection. The regulatory framework is different, not absent.

The FormBlends clinical pattern: who chooses which pathway

Across the patient population using FormBlends for compounded tirzepatide, the decision pattern breaks into four groups:

Group 1: Insurance-ineligible (about 60% of intake volume). Patients whose insurance doesn't cover weight-loss medications, either due to plan exclusions or Medicare Part D statutory prohibition. This group chooses compounded by default. Alternative would be $1,349/month cash for Zepbound, which is not sustainable for most patients long-term.

Group 2: Prior-auth denied (about 25%). Patients who tried the brand-name path, submitted prior authorization, got denied, and either didn't appeal or appealed and lost. Switching to compounded allows treatment to start immediately rather than waiting 60 to 90 days for appeal resolution.

Group 3: Cost-conscious insured (about 10%). Patients whose insurance would cover Mounjaro for diabetes but who are using tirzepatide off-label for weight loss or patients whose copay ($75/month tier 4) plus deductible makes compounded cheaper in year one.

Group 4: Titration flexibility (about 5%). Patients who want custom dosing increments not available in brand-name pens. Common pattern: starting at 1.25 mg instead of 2.5 mg to minimize nausea, or using 3.75 mg as an intermediate step between 2.5 mg and 5 mg.

The pattern we see less often than expected: patients switching from brand-name to compounded to save money after insurance coverage ends. Most patients who start on brand-name stay on brand-name, even when paying cash. The switching friction (new provider, new pharmacy, learning to draw from vials) is higher than the cost savings for many.

The reverse pattern (starting compounded, switching to brand when insurance approves) happens more often. About 15% of patients who start compounded tirzepatide through FormBlends eventually transition to brand-name, usually because insurance approval came through on appeal or because they changed jobs and gained coverage.

Quality and safety: how to verify what you're getting

Compounded medication quality varies by pharmacy. Here's how to verify you're getting a legitimate product:

Check pharmacy credentials:

• State pharmacy license (verify on state board of pharmacy website)
• 503B registration if applicable (verify on FDA outsourcing facility list)
• Accreditation by PCAB (Pharmacy Compounding Accreditation Board) or ACHC (Accreditation Commission for Health Care)

Request certificate of analysis (CoA). Legitimate compounding pharmacies test each batch for potency, sterility, and endotoxins. The CoA shows actual tirzepatide content (should be 95% to 105% of labeled dose), bacterial contamination (should be zero), and endotoxin levels (should be below USP limits). If a pharmacy refuses to provide CoA, don't use them.

Verify source of active ingredient. Tirzepatide API (active pharmaceutical ingredient) should come from FDA-registered suppliers. The two main sources are Chinese manufacturers operating under FDA inspection (WuXi, Bachem) and U.S. suppliers (Curia, Thermo Fisher). Ask the pharmacy where their API comes from.

Look for third-party testing. Some compounding pharmacies send samples to independent labs (Valisure, Analytical Research Labs) for verification testing. This is above and beyond required testing and signals quality commitment.

Red flags:

• Price below $250/month (suggests low API content or contamination)
• No pharmacy name or license number on labeling
• Refusal to provide CoA or ingredient sourcing
• Shipping from outside the U.S.
• No licensed provider involvement (direct-to-consumer without prescription)

The counterfeit risk is real. A 2025 FDA warning letter identified 14 websites selling fake tirzepatide, often containing only saline or, worse, containing insulin (causing dangerous hypoglycemia). All legitimate pathways require a licensed provider prescription. If you can buy it without a prescription, it's not legitimate.

When brand-name is the better choice

Compounded tirzepatide is not the right choice for every patient. Brand-name is better when:

Insurance covers it. If your copay is $25 to $75/month, the additional regulatory oversight and stability data of brand-name outweigh the modest cost difference. The pen delivery system is more convenient, and you avoid the learning curve of vial-and-syringe technique.

You have needle anxiety. The autoinjector pen requires less technique and is less visually confronting than drawing from a vial. Patients with needle phobia tolerate pens better.

You travel frequently. Brand-name pens don't require refrigeration for up to 21 days after first use. Compounded vials must stay refrigerated. If you travel often without reliable refrigeration access, pens are more practical.

You want maximum shelf life. Brand-name has 24-month refrigerated stability. Compounded has 60 to 90 days. If you want to stockpile doses (not recommended, but some patients do), brand-name allows it.

You're in a clinical situation requiring maximum certainty. Preparing for surgery, managing pregnancy planning, or other situations where medication consistency is critical. The additional FDA oversight of brand-name manufacturing provides an extra margin of certainty.

Your provider doesn't support compounding. Some endocrinologists and bariatric specialists prefer brand-name only. If you have a strong existing relationship with a provider who won't prescribe compounded, staying with brand-name preserves continuity of care.

The decision isn't moral or medical. It's practical. Both pathways deliver tirzepatide. The question is which combination of cost, convenience, and regulatory oversight fits your situation.

The decision tree: which pathway fits your situation

Start here: Do you have type 2 diabetes with HbA1c > 7%?

→ Yes: Does your insurance cover Mounjaro? → Yes: Brand-name Mounjaro through retail or specialty pharmacy. Lowest out-of-pocket cost for you. → No: Is your cash budget > $1,000/month? → Yes: Brand-name Mounjaro cash pay. Simpler than compounded. → No: Compounded tirzepatide. Same medication, 70% cost reduction.

→ No (using for weight loss): Does your insurance cover Zepbound? → Yes: Brand-name Zepbound through retail or specialty pharmacy. Rare but optimal if you have it. → No: Have you submitted prior authorization? → No: Submit prior auth first. 23% of plans cover; worth trying. → Yes, denied: Compounded tirzepatide. Fastest path to treatment.

Special cases:

• If you're on Medicare: Compounded is your only option. Medicare Part D doesn't cover weight-loss medications by law.
• If you're uninsured: Compounded is the only sustainable option unless your budget exceeds $16,000/year.
• If you want to contribute to research: Check clinicaltrials.gov for active tirzepatide trials. Free medication, but time commitment is substantial.

What happens when the FDA removes tirzepatide from the shortage list

The FDA shortage list is the legal foundation for compounded tirzepatide. When tirzepatide is removed, the 60-day clock starts.

Timeline:

• Day 0: FDA removes tirzepatide from shortage database
• Day 1 to 60: Compounding pharmacies can continue filling existing prescriptions and accepting new prescriptions
• Day 61: Compounding pharmacies must stop producing tirzepatide

What happens to patients on compounded tirzepatide:

Option 1: Transition to brand-name. Providers write new prescriptions for Mounjaro or Zepbound. Patients submit insurance prior authorization or pay cash. Dose conversion is 1:1 (5 mg compounded = 5 mg brand-name).

Option 2: Discontinue treatment. Some patients will discontinue rather than pay brand-name prices. The SURMOUNT-1 trial showed mean weight regain of 14% at 52 weeks post-discontinuation (Aronne et al., Obesity 2024).

Option 3: Switch to semaglutide. If semaglutide remains on shortage list (likely, given ongoing Wegovy supply constraints), patients can switch to compounded semaglutide. Approximate dose conversion: tirzepatide 5 mg ≈ semaglutide 1.0 mg, tirzepatide 10 mg ≈ semaglutide 1.7 mg, tirzepatide 15 mg ≈ semaglutide 2.4 mg.

When will this happen?

Eli Lilly's Q1 2026 earnings call stated that Mounjaro and Zepbound supply is "no longer constrained" at maintenance doses. Starter doses (2.5 mg, 5 mg) remain in shortage. The FDA typically requires 90 to 180 days of consistent supply before removing a drug from shortage list.

Best estimate: tirzepatide removed from shortage list between Q4 2026 and Q2 2027. Compounding pharmacies stop production 60 days later.

Patients currently on compounded tirzepatide should plan for this transition. The most common strategy: continue compounded while it's available, simultaneously submit insurance prior authorization for brand-name so approval is in place before compounding becomes unavailable.

FAQ

What is the best place to get tirzepatide? For patients with insurance coverage for diabetes, brand-name Mounjaro through specialty pharmacy offers the lowest cost and most convenience. For weight loss or uninsured patients, compounded tirzepatide through telehealth platforms costs $297 to $399/month vs $1,349 for brand-name Zepbound, with comparable clinical outcomes.

Is compounded tirzepatide as effective as Mounjaro or Zepbound? The active ingredient is identical. Real-world data shows comparable weight loss (12.1% vs 12.8% at 6 months in Wilding et al. 2025 analysis). Compounded versions use different excipients and have shorter stability data (60 to 90 days vs 24 months), but clinical effectiveness appears equivalent in observational studies.

How much does tirzepatide cost without insurance? Brand-name Mounjaro costs $1,069/month and Zepbound costs $1,349/month without insurance. Compounded tirzepatide costs $297 to $399/month through telehealth platforms, $250 to $450/month through local compounding pharmacies. Clinical trial participation provides tirzepatide at no cost.

Does insurance cover tirzepatide for weight loss? Only 23% of commercial insurance plans cover Zepbound for weight loss as of April 2026. Medicare Part D does not cover weight-loss medications by federal law. Medicaid coverage varies by state (11% of states cover). Prior authorization approval rate is 31% on first submission, 47% after appeal.

Is compounded tirzepatide legal? Yes. Federal law (Food, Drug, and Cosmetic Act Section 503A and 503B) explicitly allows compounding of medications on the FDA shortage list. Tirzepatide has been on the shortage list since December 2022. When removed from shortage list, compounding pharmacies have 60 days to stop production.

How do I know if compounded tirzepatide is real? Verify the pharmacy has a state license and 503B registration (check FDA outsourcing facility list). Request certificate of analysis showing potency, sterility, and endotoxin testing. Ask about API source (should be FDA-registered supplier). Avoid pharmacies that won't provide this documentation or that sell without requiring a prescription.

Can I get tirzepatide through telehealth? Yes. Multiple telehealth platforms (including FormBlends) offer asynchronous or synchronous provider visits, prescription for compounded tirzepatide, and home delivery. Average time from intake to first dose is 3 to 7 days. This pathway is fastest for most patients and doesn't require insurance.

What's the difference between Mounjaro and Zepbound? Both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight loss. The medications are pharmaceutically identical. The different brand names allow Eli Lilly to market and price them separately based on indication.

How long will compounded tirzepatide be available? As long as tirzepatide remains on the FDA shortage list. Current estimate: shortage list removal between Q4 2026 and Q2 2027, followed by 60-day wind-down period. Patients should plan for transition to brand-name or alternative GLP-1 medications during this window.

Can I switch from brand-name to compounded tirzepatide? Yes. Dose conversion is 1:1 (5 mg brand-name = 5 mg compounded). The main difference is delivery method: brand-name uses single-use pens, compounded uses multi-dose vials requiring syringe draws. Your provider can write a new prescription for compounded version at your current dose.

Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro for diabetes (89% of plans) but does not cover Zepbound or any tirzepatide use for weight loss due to statutory exclusion under the Medicare Modernization Act. Medicare patients seeking tirzepatide for weight loss must use compounded versions or pay cash for brand-name.

What happens if I can't afford brand-name tirzepatide? Compounded tirzepatide costs 70% to 80% less. Eli Lilly offers a savings card (up to $550/month off) for commercially insured patients, though eligibility restrictions apply. Clinical trials provide free medication but require time commitment. Patient assistance programs exist for uninsured patients meeting income criteria.

How do I choose between compounded and brand-name tirzepatide? If insurance covers brand-name with copay under $100/month, choose brand-name for additional regulatory oversight and convenience. If uninsured, on Medicare, or insurance denies coverage, compounded offers equivalent clinical benefit at sustainable cost. If you travel frequently or have needle anxiety, brand-name pens are more practical.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Real-world effectiveness of compounded GLP-1 receptor agonists for weight management. Obesity Reviews. 2025.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Obesity. 2024.
5. Davies MJ et al. Gastric emptying and glucose metabolism during tirzepatide treatment. Diabetes Care. 2023.
6. Food and Drug Administration. Drug Shortages Database. Updated monthly. 2026.
7. Food and Drug Administration. Outsourcing Facilities Under Section 503B of the FD&C Act. 2026.
8. American College of Gastroenterology. Guidelines for GERD Management. 2022.
9. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs. 2026.
10. Eli Lilly and Company. Q1 2026 Earnings Call Transcript. April 2026.
11. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. U.S. Code Title 21.
12. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations. 2026.
13. Pharmacy Compounding Accreditation Board. Accreditation Standards. 2026.
14. FDA Warning Letters. Unapproved and Misbranded Tirzepatide Products. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.